Circulating tumor DNA (ctDNA) monitoring in breast cancer patients receiving neoadjuvant palbociclib and endocrine therapy. A secondary analysis of the NeoRHEA phase 2 study
Literature
Read More
LIBELULE: A randomized phase III study to evaluate the clinical relevance of early liquid biopsy (LB) in patients with suspicious metastatic lung cancer
Literature
Read More
A phase II single-arm, open-label trial of T-DM1 (ado-trastuzumab emtansine) and neratinib for HER2-positive breast cancer with molecular residual disease (KAN-HER2 MRD)
Literature
Read More
Detection of circulating tumor DNA following neoadjuvant chemotherapy and surgery to anticipate early relapse in ER positive and HER2 negative breast cancer: Analysis from the PENELOPE-B trial
Literature
Read More
Multimodal detection in plasma of molecular residual disease (MRD) in locally advanced head and neck squamous cell carcinoma (LA-HNSCC)
Literature
Read More
Validation of recurrence prediction using circulating tumor DNA in patients with curatively treated early stage non-small cell lung cancer
Literature
Read More
NeoGenomics to Participate at the Goldman Sachs 44th Annual Global Healthcare Conference
Press Release
Read More
NeoGenomics to Showcase the Transformational Impact of RaDaR(R) Assay for Molecular Residual Disease and Recurrence Monitoring at ASCO
Press Release
Read More